Growth Opportunities PolyNovo is investing for growth with new products, indications and markets after treating over 106,000 patients across 46 countries, signaling expansion into adjacent wound care segments and larger geographic regions that SMB and enterprise healthcare customers may adopt.

Strategic Partnerships Recent collaborations and asset acquisitions, including DeepView System for burns with Spectral AI and exclusive rights for SUPRATHEL in the UK, Australia, and New Zealand, create co-selling opportunities and channel leverage to reach new hospital networks and wound care centers.

Regulatory and Governance New leadership appointment as general counsel and company secretary, plus ongoing manufacturing and R&D investments funded by government grants, position PolyNovo to navigate procurement, compliance, and high-value government/health system contracts more effectively.

Geographic Reach Established presence across 46 countries with strategic regional rights in UK, Northern Europe, and Europe, offering a pathway to tap public and private sector wound care purchasing cycles in mature markets with addressable trillion-dollar health spend.

Product and Tech Leverage Investment in polymer-based tissue engineering and new indications aligns with hospital demand for innovative wound management solutions, presenting opportunities to upsell expanded indications, bundled product packages, and integrated care pathways.